158 related articles for article (PubMed ID: 7800136)
1. T cell-mediated cytotoxicity of human gliomas: a tumor necrosis factor-independent mechanism.
Baltuch GH; Villemure JG; McCrea E; Antel JP
Neurosurgery; 1994 Sep; 35(3):450-6; discussion 456. PubMed ID: 7800136
[TBL] [Abstract][Full Text] [Related]
2. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
Holladay FP; Heitz T; Wood GW
J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119
[TBL] [Abstract][Full Text] [Related]
4. Reinforced cytotoxicity of lymphokine-activated killer cells toward glioma cells by transfection with the tumor necrosis factor-alpha gene.
Tashiro T; Yoshida J; Mizuno M; Sugita K
J Neurosurg; 1993 Feb; 78(2):252-6. PubMed ID: 8421207
[TBL] [Abstract][Full Text] [Related]
5. Characterization of human autotumor-reactive T-cell clones obtained from tumor-infiltrating lymphocytes in liver metastasis of gastric carcinoma.
Shimizu Y; Weidmann E; Iwatsuki S; Herberman RB; Whiteside TL
Cancer Res; 1991 Nov; 51(22):6153-62. PubMed ID: 1718596
[TBL] [Abstract][Full Text] [Related]
6. [Induction of cytotoxicity from human lymphocytes coated with bispecific antibody against human glioma cells].
Nitta T; Ishizawa A; Ito M; Sato K; Yagita H; Kumura K
No Shinkei Geka; 1990 Nov; 18(11):1001-6. PubMed ID: 2247192
[TBL] [Abstract][Full Text] [Related]
7. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
[TBL] [Abstract][Full Text] [Related]
9. Multiple cytolytic mechanisms displayed by activated human peripheral blood T cell subsets.
Smyth MJ; Norihisa Y; Ortaldo JR
J Immunol; 1992 Jan; 148(1):55-62. PubMed ID: 1345790
[TBL] [Abstract][Full Text] [Related]
10. The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma.
Jachimczak P; Bogdahn U; Schneider J; Behl C; Meixensberger J; Apfel R; Dörries R; Schlingensiepen KH; Brysch W
J Neurosurg; 1993 Jun; 78(6):944-51. PubMed ID: 8487077
[TBL] [Abstract][Full Text] [Related]
11. Adhesion molecule-mediated signals regulate major histocompatibility complex-unrestricted and CD3/T cell receptor-triggered cytotoxicity.
Galandrini R; Albi N; Zarcone D; Grossi CE; Velardi A
Eur J Immunol; 1992 Aug; 22(8):2047-53. PubMed ID: 1379184
[TBL] [Abstract][Full Text] [Related]
12. Induction of antigen-specific CD4+ HLA-DR-restricted cytotoxic T lymphocytes as well as nonspecific nonrestricted killer cells by the recombinant mycobacterial 65-kDa heat-shock protein.
Ab BK; Kiessling R; Van Embden JD; Thole JE; Kumararatne DS; Pisa P; Wondimu A; Ottenhoff TH
Eur J Immunol; 1990 Feb; 20(2):369-77. PubMed ID: 1690136
[TBL] [Abstract][Full Text] [Related]
13. Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma.
Yamanaka R; Honma J; Tsuchiya N; Yajima N; Kobayashi T; Tanaka R
J Neurooncol; 2005 Apr; 72(2):107-13. PubMed ID: 15925989
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of cytotoxicity used by human peripheral blood CD4+ and CD8+ T cell subsets. The role of granule exocytosis.
Smyth MJ; Ortaldo JR
J Immunol; 1993 Jul; 151(2):740-7. PubMed ID: 8101537
[TBL] [Abstract][Full Text] [Related]
15. Glioma cells display complex cell surface topographies that resist the actions of cytolytic effector lymphocytes.
Hoa N; Ge L; Kuznetsov Y; McPherson A; Cornforth AN; Pham JT; Myers MP; Ahmed N; Salsman VS; Lamb LS; Bowersock JE; Hu Y; Zhou YH; Jadus MR
J Immunol; 2010 Oct; 185(8):4793-803. PubMed ID: 20855883
[TBL] [Abstract][Full Text] [Related]
16. Cytolysis of malignant glioma cells by lymphokine-activated killer cells combined with anti-CD3/antiglioma bifunctional antibody and tumor necrosis factor-alpha.
Yoshida J; Takaoka T; Mizuno M; Momota H; Okada H
J Surg Oncol; 1996 Jul; 62(3):177-82. PubMed ID: 8667624
[TBL] [Abstract][Full Text] [Related]
17. Oligodendrocyte lysis by CD4+ T cells independent of tumor necrosis factor.
Antel JP; Williams K; Blain M; McRea E; McLaurin J
Ann Neurol; 1994 Mar; 35(3):341-8. PubMed ID: 7510099
[TBL] [Abstract][Full Text] [Related]
18. Cellular mechanisms of lymphocyte-mediated lysis of tumor cells.
Arancia G; Malorni W; Donelli G
Ann Ist Super Sanita; 1990; 26(3-4):369-84. PubMed ID: 2151107
[TBL] [Abstract][Full Text] [Related]
19. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
[TBL] [Abstract][Full Text] [Related]
20. [Infiltrative and cytolytic activities of lymphokine-activated killer (LAK) cells against a human glioma mass: ultrastructural analysis using a three-dimensional multicellular spheroid model].
Iwasaki K
Nihon Geka Hokan; 1990 Jan; 59(1):39-54. PubMed ID: 2130768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
